Antiphospholipid syndrome and IgA anti-beta2-glycoprotein I antibodies: when Cinderella becomes a princess

Abstract

IgA anti-beta2-glycoprotein I (IgA-aB2GPI) antibodies are currently not included as a laboratory criterion of antiphospholipid syndrome (APS). In the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, (USA) in 2010, these antibodies were accepted as an APS laboratory criterion in patients who had clinical manifestations of APS but were negative for “consensus” antiphospholipid antibodies (aPL) (IgG and IgM isotypes). Consequently, individuals with thrombotic events who are negative for consensus aPL may be undiagnosed for APS. The most recent publications have confirmed that IgA-aB2GPI antibodies are a risk factor for thrombotic events. In this viewpoint, we propose that IgA-aB2GPI antibodies should be included as an APS consensus criterion and that we have to help Cinderella become a princess.

Keywords

Anti-B2GPI APS thrombosis antiphospholipid antibodies laboratory criteria IgA

Get full access to this article

View all access options for this article.

References

Pierangeli

Liu

Barker

Anderson

Harris

. Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thromb Haemost 1995; 74: 1361–1367.

Martínez-Flores

Serrano

Alfaro

et al.

Heterogeneity between diagnostic tests for IgA anti-beta2 glycoprotein I: Explaining the controversy in studies of association with vascular pathology. Anal Chem 2013; 85: 12093–12098.

Petri

Orbai

Alarcón

et al.

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677–2686.

Lakos

Favaloro

Harris

et al.

International consensus guidelines on anticardiolipin and anti-beta2-glycoprotein I testing: Report from the 13th International Congress on Antiphospholipid Antibodies. Arthritis Rheum 2012; 64: 1–10.

Tsutsumi

Matsuura

Ichikawa

Fujisaku

Mukai

Koike

. IgA class anti-beta2-glycoprotein I in patients with systemic lupus erythematosus. J Rheumatol 1998; 25: 74–78.

Cervera

Serrano

Pons-Estel

et al.

Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: A multicentre prospective study of 1000 patients. Ann Rheum Dis 2015; 74: 1011–1018.

Tortosa

Cabrera-Marante

Serrano

et al.

Incidence of thromboembolic events in asymptomatic carriers of IgA anti ß2 glycoprotein-I antibodies. PLoS One 2017; 12: e0178889–e0178889.

Barbhaiya

Erkan

. Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: Where do we stand? Curr Rheumatol Rep 2011; 13: 59–69.

Mustonen

Lehtonen

Javela

Puurunen

. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: A nationwide prospective study. Lupus 2014; 23: 1468–1476.

10.

Artenjak

Lakota

Frank

et al.

Antiphospholipid antibodies as non-traditional risk factors in atherosclerosis based cardiovascular diseases without overt autoimmunity. A critical updated review. Autoimmun Rev 2012; 11: 873–882.